Opioid Dose- and Route-Dependent Efficacy of Oxycodone and Heroin Vaccines in Rats

Overview

Journal J Pharmacol Exp Ther

Specialty Pharmacology

Date 2018 Mar 15

PMID 29535156

Citations 33

Authors

Michael D Raleigh

Megan Laudenbach

Federico Baruffaldi

Samantha J Peterson

Michaela J Roslawski

Angela K Birnbaum

F Ivy Carroll

Scott P Runyon

Scott Winston

Paul R Pentel

Marco Pravetoni

Affiliations

Soon will be listed here.

Abstract

Heroin and oxycodone abuse occurs over a wide range of drug doses and by various routes of administration characterized by differing rates of drug absorption. The current study addressed the efficacy of a heroin vaccine [morphine hapten conjugated to keyhole limpet hemocyanin (M-KLH)] or oxycodone vaccine [oxycodone hapten conjugated to keyhole limpet hemocyanin (OXY-KLH)] for reducing drug distribution to brain after intravenous heroin or oxycodone, or subcutaneous oxycodone. Rats immunized with M-KLH or keyhole limpet hemocyanin (KLH) control received an intravenous bolus dose of 0.26 or 2.6 mg/kg heroin. Vaccination with M-KLH increased retention of heroin and its active metabolites 6-acetylmorphine (6-AM) and morphine in plasma compared with KLH controls, and reduced total opioid (heroin + 6-AM + morphine) distribution to brain but only at the lower heroin dose. Immunization also protected against respiratory depression at the lower heroin dose. Rats immunized with OXY-KLH or KLH control received 0.22 or 2.2 mg/kg oxycodone intravenously, the molar equivalent of the heroin doses. Immunization with OXY-KLH significantly reduced oxycodone distribution to brain after either oxycodone dose, although the magnitude of effect of immunization at the higher oxycodone dose was small (12%). By contrast, vaccination with OXY-KLH was more effective when oxycodone was administered subcutaneously rather than intravenously, reducing oxycodone distribution to brain by 44% after an oxycodone dose of 2.3 mg/kg. Vaccination also reduced oxycodone-induced antinociception. These data suggest that the efficacy of OXY-KLH and M-KLH opioid vaccines is highly dependent upon opioid dose and route of administration.

Citing Articles

The development of opioid vaccines as a novel strategy for the treatment of opioid use disorder and overdose prevention.

Tuncturk M, Kushwaha S, Heider R, Heider BS R, Oesterle T, Weinshilboum R Int J Neuropsychopharmacol. 2025; 28(2).

PMID: 39831679 PMC: 11792077. DOI: 10.1093/ijnp/pyaf005.

Opioid-Based Haptens: Development of Immunotherapy.

Hosztafi S, Galambos A, Koteles I, Karadi D, Furst S, Al-Khrasani M Int J Mol Sci. 2024; 25(14).

PMID: 39063024 PMC: 11277321. DOI: 10.3390/ijms25147781.

From hit to vial: Precision discovery and development of an imidazopyrimidine TLR7/8 agonist adjuvant formulation.

Soni D, Borriello F, Scott D, Feru F, DeLeon M, Brightman S Sci Adv. 2024; 10(27):eadg3747.

PMID: 38959314 PMC: 11221515. DOI: 10.1126/sciadv.adg3747.

Comparing withdrawal- and anxiety-like behaviors following oral and subcutaneous oxycodone administration in C57BL/6 mice.

De Almeida S, Drinkuth C, Sartor G Behav Pharmacol. 2024; 35(5):269-279.

PMID: 38847447 PMC: 11226370. DOI: 10.1097/FBP.0000000000000780.

Vaccines to Treat Substance Use Disorders: Current Status and Future Directions.

Lu T, Li X, Zheng W, Kuang C, Wu B, Liu X Pharmaceutics. 2024; 16(1).

PMID: 38258095 PMC: 10820210. DOI: 10.3390/pharmaceutics16010084.

References

Oviedo-Joekes E, March J, Romero M, Perea-Milla E . The Andalusian trial on heroin-assisted treatment: a 2 year follow-up. Drug Alcohol Rev. 2010; 29(1):75-80. DOI: 10.1111/j.1465-3362.2009.00100.x. View

Jalah R, Torres O, Mayorov A, Li F, Antoline J, Jacobson A . Efficacy, but not antibody titer or affinity, of a heroin hapten conjugate vaccine correlates with increasing hapten densities on tetanus toxoid, but not on CRM197 carriers. Bioconjug Chem. 2015; 26(6):1041-53. PMC: 4472500. DOI: 10.1021/acs.bioconjchem.5b00085. View

Anton B, Leff P . A novel bivalent morphine/heroin vaccine that prevents relapse to heroin addiction in rodents. Vaccine. 2006; 24(16):3232-40. DOI: 10.1016/j.vaccine.2006.01.047. View

Schlosburg J, Vendruscolo L, Bremer P, Lockner J, Wade C, Nunes A . Dynamic vaccine blocks relapse to compulsive intake of heroin. Proc Natl Acad Sci U S A. 2013; 110(22):9036-41. PMC: 3670323. DOI: 10.1073/pnas.1219159110. View

Raleigh M, Peterson S, Laudenbach M, Baruffaldi F, Carroll F, Comer S . Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse. PLoS One. 2017; 12(12):e0184876. PMC: 5711015. DOI: 10.1371/journal.pone.0184876. View

Pravetoni M, Le Naour M, Tucker A, Harmon T, Hawley T, Portoghese P . Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens. J Med Chem. 2012; 56(3):915-23. PMC: 3791856. DOI: 10.1021/jm3013745. View

Backonja M, Webster L, Setnik B, Bass A, Sommerville K, Matschke K . Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid users. Am J Drug Alcohol Abuse. 2016; 42(5):539-549. DOI: 10.3109/00952990.2016.1167215. View

Laudenbach M, Baruffaldi F, Vervacke J, Distefano M, Titcombe P, Mueller D . The frequency of naive and early-activated hapten-specific B cell subsets dictates the efficacy of a therapeutic vaccine against prescription opioid abuse. J Immunol. 2015; 194(12):5926-36. PMC: 4458396. DOI: 10.4049/jimmunol.1500385. View

Esterlis I, Hannestad J, Perkins E, Bois F, DSouza D, Tyndale R . Effect of a nicotine vaccine on nicotine binding to β2*-nicotinic acetylcholine receptors in vivo in human tobacco smokers. Am J Psychiatry. 2013; 170(4):399-407. PMC: 3738000. DOI: 10.1176/appi.ajp.2012.12060793. View

10.

Renard C, Scherrmann J . Pharmacokinetics of heterologous and homologous immunoglobulin G, F(ab')2 and Fab after intravenous administration in the rat. J Pharm Pharmacol. 1997; 49(3):277-81. DOI: 10.1111/j.2042-7158.1997.tb06795.x. View

11.

Raleigh M, Pravetoni M, Harris A, Birnbaum A, Pentel P . Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroin-induced behaviors in rats. J Pharmacol Exp Ther. 2012; 344(2):397-406. PMC: 3558830. DOI: 10.1124/jpet.112.201194. View

12.

Rosenberg H, Phillips K . Acceptability and availability of harm-reduction interventions for drug abuse in American substance abuse treatment agencies. Psychol Addict Behav. 2003; 17(3):203-10. DOI: 10.1037/0893-164X.17.3.203. View

13.

Raleigh M, Pentel P, Lesage M . Pharmacokinetic correlates of the effects of a heroin vaccine on heroin self-administration in rats. PLoS One. 2014; 9(12):e115696. PMC: 4275252. DOI: 10.1371/journal.pone.0115696. View

14.

Strang J, Metrebian N, Lintzeris N, Potts L, Carnwath T, Mayet S . Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial. Lancet. 2010; 375(9729):1885-95. DOI: 10.1016/S0140-6736(10)60349-2. View

15.

Paulozzi L . Prescription drug overdoses: a review. J Safety Res. 2012; 43(4):283-9. DOI: 10.1016/j.jsr.2012.08.009. View

16.

Pravetoni M, Pentel P, Potter D, Chartoff E, Tally L, Lesage M . Effects of an oxycodone conjugate vaccine on oxycodone self-administration and oxycodone-induced brain gene expression in rats. PLoS One. 2014; 9(7):e101807. PMC: 4099132. DOI: 10.1371/journal.pone.0101807. View

17.

Poyhia R, Seppala T, Olkkola K, Kalso E . The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol. 1992; 33(6):617-21. PMC: 1381353. DOI: 10.1111/j.1365-2125.1992.tb04090.x. View

18.

Hatsukami D, Jorenby D, Gonzales D, Rigotti N, Glover E, Oncken C . Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin Pharmacol Ther. 2011; 89(3):392-9. PMC: 4106715. DOI: 10.1038/clpt.2010.317. View

19.

Pravetoni M, Keyler D, Pidaparthi R, Carroll F, Runyon S, Murtaugh M . Structurally distinct nicotine immunogens elicit antibodies with non-overlapping specificities. Biochem Pharmacol. 2011; 83(4):543-50. PMC: 3259188. DOI: 10.1016/j.bcp.2011.11.004. View

20.

Pravetoni M, Raleigh M, Le Naour M, Tucker A, Harmon T, Jones J . Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats. Vaccine. 2012; 30(31):4617-24. PMC: 3372705. DOI: 10.1016/j.vaccine.2012.04.101. View